GSK to use Owlstone’s breath biopsy in COPD trial
In a major boon for UK diagnostics group Owlstone Medical, GlaxoSmithKline is incorporating the firm’s Breath Biopsy platform into the clinical development programme for its novel, experimental respiratory drug danirixin.
Read More
